Sarepta Therapeutics Inc

Research Sarepta Therapeutics Inc (SRPT) on Bullrun: market cap USD 2.00B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 2.00B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 1.86B-USD 713.41M-USD 307.45M98.6%-7.13USD 801.28MUSD 828.97MUSD 1.14B
FY2024USD 1.79BUSD 235.24M-USD 342.74M88.5%2.34USD 1.10BUSD 1.14BUSD 1.53B
FY2023USD 1.14B-USD 535.98M-USD 577.10Mn/a-5.8USD 428.43MUSD 1.34BUSD 859.34M
FY2022USD 843.77M-USD 703.49M-USD 356.17Mn/a-8.03USD 966.78MUSD 1.54BUSD 384.95M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 2.00Bn/an/an/a
20252025-12-31USD 2.26Bn/an/an/a
20242024-12-31USD 11.78B51.1n/an/a
20232023-12-29USD 9.02Bn/an/an/a
20222022-12-30USD 11.37Bn/an/an/a
20212021-12-31USD 7.85Bn/an/an/a

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Sarepta Therapeutics Inc's market cap?

Sarepta Therapeutics Inc's market capitalization is USD 2.00B.

What does Sarepta Therapeutics Inc do?

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.